Stock Fundamentals

Company Information

Company Name
Bicycle Therapeutics Ltd
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US0887861088
CIK: 0001761612
CUSIP: 088786108
Currency: USD
Full Time Employees: 288
Phone: 44 1223 261 503
Fiscal Year End: December
IPO Date: May 23, 2019
Description:

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Address:

Portway Building, Cambridge, United Kingdom, CB21 6GS

Directors & Officers

Name Title Year Born
Dr. Kevin Lee M.B.A., Ph.D. CEO & Executive Director 1968
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Ph.D. Co-Founder & Independent Non-Executive Director 1951
Dr. Michael Skynner B.sc. Ph.d., Ph.D. Chief Scientific Officer 1969
Mr. Alistair Milnes Chief Corporate Development Officer 1974
Dr. Christian Heinis Scientific Founder NA
Mr. Travis Thompson Chief Financial Officer 1980
Dr. Jennifer Perry Pharm.D. Chief Operating Officer 1974
Ms. Stephanie Yao Senior Vice President of Investor Relations and Corporate Communications NA
Mr. Zafar Qadir Chief Legal Officer & General Counsel NA
Dr. Phil Jeffrey Senior VP of Pre-Clinical Development NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 06, 2026 Kevin Lee N/A Sale 1.72K $5.05 $8.67K
Apr 06, 2026 Travis Alvin Thompson N/A Sale 102.00 $5.05 $515.10
Apr 06, 2026 Jennifer Scott Perry N/A Sale 370.00 $5.04 $1.86K
Apr 02, 2026 Jennifer Scott Perry N/A Sale 1.04K $4.91 $5.10K
Apr 02, 2026 Kevin Lee N/A Sale 5.97K $4.91 $29.30K
Apr 02, 2026 Travis Alvin Thompson N/A Sale 799.00 $4.91 $3.92K
Jan 05, 2026 Alethia Young N/A Sale 4.33K $6.49 $28.13K
Jan 05, 2026 Alistair Milnes N/A Sale 3.42K $6.46 $22.07K
Jan 05, 2026 Kevin Lee N/A Sale 10.99K $6.46 $70.99K
Jan 05, 2026 Travis Alvin Thompson N/A Sale 1.12K $6.45 $7.19K
Jan 02, 2026 Alethia Young N/A Sale 3.29K $6.80 $22.37K
Jan 02, 2026 Alistair Milnes N/A Sale 3.24K $6.80 $22.06K
Jan 02, 2026 Kevin Lee N/A Sale 10.33K $6.80 $70.21K
Jan 02, 2026 Travis Alvin Thompson N/A Sale 1.32K $6.80 $8.96K
Oct 03, 2025 Alistair Milnes N/A Sale 978.00 $8.41 $8.22K
Oct 03, 2025 Travis Alvin Thompson N/A Sale 103.00 $8.41 $866.23
Oct 03, 2025 Kevin Lee N/A Sale 3.23K $8.41 $27.17K
Oct 02, 2025 Alethia Young N/A Sale 482.00 $8.51 $4.10K
Oct 02, 2025 Alistair Milnes N/A Sale 1.15K $8.40 $9.63K
Oct 02, 2025 Kevin Lee N/A Sale 2.26K $8.40 $19.01K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Baker Bros Advisors LP 10.89M Mar 31, 2026 15.59% $0.29 0.00%
FCPM III SERVICES BV 3.47M Mar 31, 2026 4.97% $2.23 0.00%
Armistice Capital, LLC 3.40M Mar 31, 2026 4.87% $0.28 5.01%
Long Focus Capital Management, LLC 3.31M Mar 31, 2026 4.74% $0.40 102.73%
Acadian Asset Management LLC 1.97M Mar 31, 2026 2.82% $0.01 0.00%
Siren, L.L.C. 1.56M Mar 31, 2026 2.24% $0.20 -22.45%
GSK PLC 1.53M Mar 31, 2026 2.19% $1.18 0.00%
Principal Financial Group Inc 1.17M Mar 31, 2026 1.68% $0.00 2.30%
T. Rowe Price Associates, Inc. 1.03M Mar 31, 2026 1.47% $0.00 -12.25%
Renaissance Technologies Corp 979.30K Mar 31, 2026 1.40% $0.01 72.84%
Morgan Stanley - Brokerage Accounts 618.33K Mar 31, 2026 0.89% $0.00 32.91%
Schroder Investment Management Group 615.83K Mar 31, 2026 0.88% $0.00 5.31%
Diadema Partners LP 476.42K Mar 31, 2026 0.68% $0.38 0.00%
Birchview Capital, LP 463.60K Mar 31, 2026 0.66% $1.22 0.19%
Silvercrest Asset Management Group LLC 428.68K Mar 31, 2026 0.61% $0.01 -10.12%
Marshall Wace Asset Management Ltd 377.34K Mar 31, 2026 0.54% $0.00 872.64%
Citadel Advisors Llc 377.09K Mar 31, 2026 0.54% $0.00 38.95%
Qube Research & Technologies 308.62K Mar 31, 2026 0.44% $0.00 0.00%
Millennium Management LLC 283.99K Mar 31, 2026 0.41% $0.00 -13.05%
BlackRock Inc 278.99K Mar 31, 2026 0.40% $0.00 -16.19%

Shares Statistics

Shares Outstanding: 50.37M
Shares Float: 1.88M
% Insiders: 448.70%
% Institutions: 7,364.90%
Short % Float: 7.36%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Candriam Eqs L Biotech C USD Cap 825.13K 1.18% ▲ 0.00% Nov 30, 2025
2 T. Rowe Price Health Sciences 628.42K 0.90% ▼ 14.99% Apr 30, 2026
3 International Biotechnology Ord 615.83K 0.88% ▲ 0.00% Feb 28, 2026
4 Principal U.S. Small Cap Equity 523.30K 0.75% ▼ 7.84% Mar 31, 2026
5 Principal U.S. Small Cap Select Equity 523.30K 0.75% ▼ 7.84% Mar 31, 2026
6 Principal SmallCap R5 516.10K 0.74% ▼ 1.38% Apr 30, 2026
7 Belfius Equities Cure C Cap 367.15K 0.53% ▲ 0.00% Nov 30, 2025
8 Old Westbury Small & Mid Cap Strategies 265.97K 0.38% ▲ 25.27% Jan 31, 2026
9 iShares Biotechnology ETF 238.51K 0.34% ▲ 1.95% May 29, 2026
10 BlueBox Precision Medicine S USD Acc 134.83K 0.19% ▲ 0.00% Feb 28, 2026

Valuation Metrics

Enterprise Value: $-261.40M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $282.74M
EBITDA: $-232.23M
Book Value: $7.95
Earnings/Share: $-3.15
Profit Margin: 0.00%
Operating Margin: -7,382.41%
ROA (TTM): -19.38%
ROE (TTM): -33.84%
Revenue (TTM): $63.50M
Revenue/Share (TTM): $0.92
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -91.10%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 11.02x 0.00x 0.15x -1,202.51x -0.01x
2024-12-31 13.81x 0.01x 0.17x -121.31x -0.03x
2023-12-31 8.08x 0.10x 0.38x -58.21x -0.21x
2022-12-31 6.92x 0.12x 0.34x -34.88x -0.31x
2021-12-31 12.65x 0.09x 0.28x -21.99x -0.50x
2020-12-31 6.73x 0.16x 0.41x -113.70x -0.30x
2019-12-31 11.81x 0.01x 0.15x -7.30x -0.03x
2018-12-31 8.60x 0.00x 1.86x N/A 0.00x
2017-12-31 7.57x -0.07x 1.64x N/A -0.21x
2016-12-31 2.96x 0.00x 0.32x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about BCYC.US!